Subscribe To
Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023
– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ca...
October 22, 2023, 8:25 am
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for ...
June 3, 2023, 8:00 pm